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The Centers for Disease Control and Prevention’s
National Program of Cancer Registries is a federally fund-
ed surveillance program that provides support and assis-
tance to state and territorial health departments for the
operation of cancer registries. The objective of this study
was to identify factors associated with the Centers for
Disease Control and Prevention’s costs to report cancer
cases during the first 5 years of the National Program of
Cancer Registries.
Methods
Information on expenditures and number of cases
reported through the National Program of Cancer
Registries was used to estimate the average cost per case
reported for each state program. Additional information
was obtained from other sources, and regression analyses
were used to assess the contribution of each factor.
Results
Average costs of the National Program of Cancer
Registries differed substantially among programs and
were inversely associated with the number of cases report-
ed (P < .001). The geographic area of the state was posi-
tively associated with the cost (P = .01), as was the region-
al cost of living (P = .08), whereas the program type (i.e.,
enhancement or planning) was inversely associated with
cost (P = .08).
Conclusion
The apparent existence of economies of scale suggests
that contiguous state programs might benefit from sharing
infrastructure and other fixed costs, such as database
management resources, depending on the geographic area
and population size served. Sharing database manage-
ment resources might also promote uniform data collection
and quality control practices, reduce the information-shar-
ing burden among states, and allow more resources to be
used for other cancer prevention and control activities.
Introduction
Cancer incidence data
The National Institutes of Health (NIH) estimated that
in 2003, the annual direct and indirect costs of cancer were
approximately $189.5 billion (1). Despite the recent
reports of a decrease in age-adjusted cancer death rates (2-
5), costs are likely to increase. Because of the growth and
the aging of the U.S. population, the total number of 
cancer cases is estimated to double by 2050 if current 
incidence rates remain stable (6). However, effective 
prevention and treatment measures exist that could sub-
stantially reduce the number of cases and prevent many
cancer-related deaths (7). To reduce the cancer burden,
particularly among medically underserved populations,
high-quality screening and treatment services must be
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available and accessible to all segments of the U.S. popu-
lation (8). Cancer incidence data from population-based
cancer registries will become increasingly more important
for identifying and targeting populations at high risk for
developing cancer. In addition, these data are helpful for
monitoring progress toward meeting cancer prevention
and control goals such as those established by Healthy
People 2010 (9).
Data from the Centers for Disease Control 
and Prevention’s (CDC’s) federally funded state- or 
territory-managed surveillance programs, including the
National Program of Cancer Registries (NPCR), are rou-
tinely used to report the incidence (i.e., new occurrence) of
diseases and track the health of the U.S. population 
(10-12). The operating efficiency of these surveillance 
programs can be examined by comparing the various pro-
grams’ average cost to report a case of disease. A compari-
son of average costs of these programs, in addition to an
exploration of variations in average costs, can help guide
current and future program planning and evaluation.
The purpose of our analysis was to gain insight into fac-
tors associated with the average NPCR cost to report an
incident case of cancer through population-based cancer
registry programs funded during the NPCR’s first 5 years.
Background of the National Program of Cancer Registries
Before the NPCR was established, many states did not
have a cancer registry, and the states that did generally
lacked the resources and legislative support to collect high-
quality data that were complete and timely (13). In 1992,
the U.S. Congress recognized the need for more local and
state cancer data and passed the Cancer Registries
Amendment Act (Public Law 102-515) (14), which author-
ized the CDC to establish the NPCR. In 1994, the NPCR
began providing financial support and technical assistance
to state health departments for the operation of statewide,
population-based cancer registries. State health depart-
ments or their authorized designees became eligible for
one of two categories of funding. The enhancement catego-
ry of funding supported the operation of existing cancer
registries. Enhancement programs continued to receive
their current level of state funding (i.e., the funding they
received at the time of initial funding from the CDC) and
contributed, or matched, $1 of state funds for every $3 of
federal funds received. Matching funds were financial or
direct (i.e., in-kind) assistance. The second category of
funding involved planning and implementing a new cancer
registry in a state with no previous registry. These plan-
ning programs were not required to match federal funds
with state funds.
After the first program announcement (15) in 1994 and
the approval of a congressional appropriation of $16.8 mil-
lion, 42 states and the District of Columbia were awarded
funds (34 enhancement programs and 9 planning pro-
grams). After the second program announcement (16) in
1997, three additional states and three territories were
awarded funds (two enhancement programs and four plan-
ning programs). As of 1999, the last year of the NPCR’s
first 5-year period, with a congressional appropriation of
$24.3 million, 45 states, the District of Columbia, and 3
territories were receiving federal support for the operation
of population-based cancer registries.
Cancer registries in the remaining five states
(Connecticut, Hawaii, Iowa, New Mexico, and Utah)
receive federal support from the National Cancer
Institute’s (NCI’s) Surveillance, Epidemiology, and End
Results (SEER) Program (17). The SEER Program also
operates six cancer registries in metropolitan areas
(Atlanta, Detroit, Los Angeles, San Francisco–Oakland,
Seattle–Puget Sound, and San Jose–Monterey) and col-
lects data on special (i.e., minority) populations in Alaska,
Arizona, and Georgia. SEER metropolitan-area and spe-
cial-population cancer registries report their incidence
data to NCI and the NPCR-funded statewide cancer reg-
istries in their respective states.
NPCR-funded cancer registries are required to collect
and report information on all state residents who are diag-
nosed or treated with in situ or invasive cancer, including
residents who are diagnosed and treated outside their
state of residence. In 2000, the CDC began to receive, eval-
uate, and publish data from participating cancer registry
programs (18). NPCR registries are required to report
incidence data annually beginning with their reference
year, which is the first year in which they collected data
with the assistance of NPCR funds. The reference year
varies among NPCR programs according to the year the
state began receiving federal funds and the amount of time
required to plan and implement a program to begin col-
lecting and reporting cancer incidence data.
To promote standardization among state programs, can-
cer registries collect and report data using uniform codes
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Association of Central Cancer Registries (NAACCR) (19).
The SEER Program and the NPCR work closely with the
NAACCR to promote the collection and publication of 
high-quality cancer incidence data; high-quality data meet
national data standards for completeness of case ascertain-
ment, timeliness, and quality (20,21). In 2002, in collabora-
tion with the NAACCR, the CDC and the NCI began pub-
lishing the United States Cancer Statistics surveillance
reports. The reports comprise data that have been reported
to the two federally funded programs (SEER and NPCR)
and have met evaluation criteria developed by the NAAC-
CR to identify registries with high-quality data (10,11).
Methods
Eligible programs
Figure 1 provides information about data collection and
reporting by NPCR-funded state cancer registries during
the project’s first 5-year period. Thirty-seven programs
began receiving funds in 1994 — 27 to report on cases
beginning in 1995, 7 to report on cases beginning in 1996,
and 3 to report on cases beginning in 1997. Six additional
programs received funds in May 1995 to report on cases
beginning in 1996. One additional program received funds
in 1997 so that it could begin reporting cases in 1997.
To be eligible for inclusion in this analysis, state health
departments or their designees 1) had to have received fed-
eral funds from the NPCR and 2) by 2002, had to have col-
lected and reported cancer incidence data to the CDC for
at least 2 consecutive years. The analysis was restricted to
43 state programs and the District of Columbia (referred
to collectively as states). Information on territory-managed
programs was not available for this analysis. The remain-
ing two states (South Dakota and Tennessee) and three
territories (Puerto Rico, the Republic of Palau, and the
Virgin Islands) received funding beginning in 1997 and
1998 and began reporting data beginning in 1999 or 2000,
so they were not eligible for inclusion in this analysis.
Cases registered
Each January, the cancer registries report their cumu-
lative incidence data to the CDC, beginning with their ref-
erence year. For this analysis, we used the total number of
incident cases (in situ and invasive) diagnosed from the
state’s reference year through 1999 (as reported to the
CDC in January 2002, approximately 24 months after the
close of the 1999 diagnosis year) (Figure 1). The diagnosis
year is the calendar year in which the cancer case was
diagnosed.
National Program of Cancer Registries costs
We obtained the amounts of federal funds allocated to
state health departments (or their designees) from the
Grant Management Information System (GMIS) main-
tained by the CDC. GMIS contains information on federal
funds that were available to each state program at the
beginning of each grant period and the amount that
remained unused at the end. We calculated the NPCR cost
for each year by subtracting the amount of unused funds
from the amount awarded. We converted these costs to
year 2000 dollars using the U.S. consumer price index
(CPI) (22). Grant periods were from October through
September of the following year, with the exception of six
state programs that received their initial funding begin-
ning in May 1996. In addition, in the last year of funding
(1999), the states received a 9-month cost extension that
ended on June 30, 2000 (Figure 1).
National Program of Cancer Registries cost per case
reported
Registries are expected to report high-quality incidence
data to the CDC approximately 24 months after the close
of each diagnosis year. However, resources spent in a
given grant period cannot be apportioned to the year cases
were diagnosed because in any given grant period, 
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Figure 1. Federal funding and data collection and reporting activities of
state cancer registries supported by the National Program of Cancer
Registries (NPCR) during the first 5-year project period. Data from 43 states
and the District of Columbia are included.VOLUME 2: NO. 3
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registries can use a portion of their federal funds to collect
current incidence data and use the remaining funds to pre-
pare previous years’ incidence data for reporting to the
CDC. For example, federal funds from grant periods in the
October 1998 to June 2000 time frame were used to collect
and report data for cases diagnosed in 1999.
Because we could not determine how much federal
money from each grant period was used to report incident
cases for a particular diagnosis year, we decided to calcu-
late the average monthly funds spent in the period that 1)
began with each program’s reference month and year and
2) ended on June 30, 2000. We multiplied this amount by
12 to determine the average annual federal funds spent.
We estimated the average number of cases diagnosed each
year by adding the total number of cases reported, begin-
ning with the program’s reference year and ending with
1999 incident cases. We determined the average annual
number of reported cases by dividing the total number of
cases by the number of diagnosis years as reported to the
CDC. Dividing the average annual federal funds spent by
the average annual number of cases reported yielded an
estimate of the average annual NPCR cost to report an
incident case of cancer for each NPCR-funded state sur-
veillance program. Before collecting and reporting data,
planning programs had a 1- to 2-year start-up period in
which they planned and implemented their cancer 
registries. Because no output measures (i.e., number of
cases) were tracked during the start-up period, we did 
not consider the amount of federal funds spent during 
this time when calculating average NPCR costs for 
planning programs.
Explanatory factors
Scatter plots suggested a curvilinear relationship
between average cost (the dependent variable) and num-
ber of cases reported (the output levels), so we used log–log
transformations of these variables. In addition to output
levels, we examined other registry characteristics, includ-
ing the way in which the funding was administered (i.e.,
by the state health department or a designee); whether the
state program was an existing (enhancement) or a new
(planning) program; whether the state program had high-
quality data, such as the 1999 incidence data that were
published in the United States Cancer Statistics: 1999
–2001 Incidence and Mortality report (10); and whether
the state had a SEER metropolitan-area cancer registry
(Georgia, Michigan, California, and Washington), a 
special-population cancer registry (Arizona, Alaska, and
Georgia), or both (Georgia) operating within its catchment
area. We also considered the following state characteris-
tics in the analysis: the cost of living as estimated by the
2000 regional CPI (22), the state’s composition (urban or
rural, expressed as the percentage of the population that
resided in an urban area) (23), and the geographic area of
the state (expressed per 1000 sq miles) (24). To estimate
the cost of living, we assigned the 2000 regional CPIs (for
the West, Midwest, South, and Northeast) to the state pro-
gram (22) and treated the values as continuous variables
for the purpose of analysis.
Statistical analysis
We used linear regression analyses to assess the rela-
tionship between the log average NPCR cost per case
reported and explanatory factors. Using SAS, version 8
(SAS Institute Inc, Cary, NC), we performed multivariate
modeling with backward elimination (25). We fit a full
model (with all variables included) and assessed the con-
tribution of each individual variable separately while
simultaneously adjusting for all other specified variables.
We sequentially eliminated variables until the final (par-
simonious) model contained only variables with a P value
of .10 or less. Because of the relatively small number of
observation units (n = 44) and the potential for confound-
ing, we used a less conservative P value so that we would
not eliminate potentially important explanatory factors.
We assessed the goodness of fit of the model by examining
the adjusted R2 value. Subset analyses, in which the best
models contained one, two, three, or more variables, were
used to verify the model selection results (26). We used the
parsimonious model to predict the average NPCR cost per
case reported for each NPCR registry.
Results
The average annual federal funds spent, the average
annual number of cases reported, and the average NPCR
cost per case reported varied substantially among state
programs (Table 1; Figure 2). The mean average annual
federal funds spent by an NPCR-funded program was
$382,698, and the median was $312,698, with a range of
$120,464 (Delaware) to $1,080,370 (Texas). The mean
average number of annual cases (in situ and invasive)
reported by an NPCR-funded program was 27,353, and the
median was 18,999, with a range of 1929 (Alaska) to
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annual NPCR cost per case reported for all programs was
$29.20, and the median was $18.43, with a range of $3.45
(Michigan) to $234.52 (Alaska).
Table 2 shows the distribution of explanatory variables
among cancer registries. Nine (20.5%) of 44 state 
health departments (California, Florida, Idaho, Kansas,
Kentucky, Louisiana, Maryland, New Hampshire,  and
Rhode Island) designated third-party organizations to
receive and administer NPCR-awarded federal funds to
operate their cancer registries. Of the 44 state programs
receiving federal funds, 35 enhancement programs
(79.5%) had an existing cancer registry at the time of
NPCR funding, and the remaining 9 planning programs
(20.5%) were newly established cancer registries. Thirty-
three (75.0%) programs had 1999 incidence data that met
the United States Cancer Statistics publication criteria
for high-quality data. Six (13.6%) programs had one or
more SEER Program registries operating within their
catchment areas. Of the 44 state programs, 16 (36.4%)
were in the South, 10 (22.7%) were in the Midwest, 10
(22.7%) were in the West, and 8 (18.2%) were in the
Northeast. The average percentage of the population that
lived in an urban area (based on the 1990 census) was
68.4%, with a range of 32.2% (Vermont) to 100.0%
(District of Columbia). The average geographic area of
the state programs was 7194 sq miles, with a range of
61.4 sq miles (District of Columbia) to 570,374 sq miles
(Alaska).
The results (Table 3) from the full model (all variables
included) revealed that the log average NPCR cost per
case reported decreased as the log of the total number of
annual cases reported increased (P ≤ .001). The log 
average NPCR cost per case reported increased as 
the geographic area of the state (expressed per 1000 sq
miles) increased (P = .03). The results did not appreciably
change when we did not include Alaska, the state with 
the largest geographic area in the analysis. The log 
average NPCR cost per case reported was lower (P = .07)
for enhancement programs than for planning programs.
The log average NPCR cost per case increased (P = .12) for
registries as the cost of living in the state increased. The
increase in the log average NPCR cost per case reported
for states with data that met the criteria for reporting
high-quality 1999 incidence data was not statistically sig-
nificant (P = .65). Similarly, the log average annual NPCR
cost per case reported was not associated (P = .66) with
the percentage of the population living in an urban area.
No association was found between the log average cost per
case and 1) whether the state had a SEER metropolitan-
area or special-population registry collecting and report-
ing cases within an NPCR catchment area (P = .78) or 2)
whether the state health departments designated a third
party to administer the cancer registry (P = .96).
We used results from the parsimonious regression model
(Table 3), containing the log average annual number of
cases reported, the type of funding (enhancement or plan-
ning), the regional CPI, and the geographic area of the
state (per 1000 sq miles), to estimate the predicted log
average annual cost per case for each program. The
observed and predicted log average NPCR costs per case
are shown in Figure 2. The cost per case reported
decreased, whereas the log average number of cases
reported increased. However, an examination of the pre-
dicted values shows that other factors need to be consid-
ered when predicting average NPCR costs.
Discussion
During the first 5-year project period of the NPCR,
notable progress was made toward establishing an infra-
structure for nationwide cancer surveillance (27,28). In
recent years, the NPCR’s focus has broadened to include
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Figure 2. Observed and predicted log average National Program of Cancer
Registries (NPCR) cost per case reported compared with the log of number
of cases reported for programs participating in the first 5-year funding peri-
od of the program. Model contained average annual number of cancer
cases reported, area (per 1000 sq miles), NPCR program type (enhance-
ment or planning), and the 2000 consumer price index.VOLUME 2: NO. 3
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working with state and national partners to use collected
data to target prevention, screening, and treatment serv-
ices directed at high-risk populations (27). Improving the
operational efficiencies of cancer registries will allow more
state and federal resources to be used for cancer preven-
tion and control — the original purpose of cancer reg-
istries. To guide program funding and management deci-
sions and ensure the availability of funds for data analysis
and interpretation, we must identify factors that influence
the cost to report a case of cancer.
Economies of scale
The major finding of this analysis is that the average
NPCR cost to report a case of cancer decreases as output
levels (i.e., incident cases) increase. Such an apparent
economies-of-scale relationship was found in an economic
analysis of the CDC’s National Breast and Cervical Cancer
Early Detection Program (NBCCEDP), in which the out-
put measure was the number of women screened for
breast and cervical cancer and the number of cancer cases
detected through screening (29). As in the NBCCEDP
analysis, the apparent existence of an economies-of-scale
relationship in this analysis is most likely a result of fixed
costs, such as administrative and infrastructure support.
The average cost per case is lower when fixed costs are
shared among more units of output. For example, each
state program must provide administrative and technical
support for the operation of the cancer registry — fixed
costs that occur regularly, whether 1000 or 100,000 new
cases of cancer are reported annually. Programs that
report a higher number of incident cases experience a
decrease in the average cost with their increase in output.
The average NPCR cost to report a case of cancer
increases with increasing geographic coverage. Although
cancer registries encourage electronic data reporting from
outlying reporting facilities (e.g., hospital cancer reg-
istries, pathology laboratories, treatment facilities), rou-
tine surveillance and quality-assurance activities often
involve visits from central cancer registry staff members to
doctors’ offices and hospitals to ensure that all incident
cancer cases are reported accurately and in a timely man-
ner. Increased geographic coverage may result in the hir-
ing of additional staff members to coordinate regional
activities. The compensation of the additional employees
and their subsequent travel-related expenses increase the
average cost to report a case.
In addition, the average NPCR cost to report a case of
cancer is higher in regions of the United States with high-
er costs of living (as measured by the regional CPI).
General operating costs, including employee compensa-
tion, are higher in New England than in the South, where
living costs are lower.
On average, incident cases of cancer cost less to report
through an enhancement program than through a plan-
ning program. This finding is not surprising, given that
enhancement programs receive maintenance and match-
ing funds from their respective state health departments,
whereas states are not required to provide financial sup-
port to planning programs. In addition, enhancement pro-
grams were established before they began receiving NPCR
funding, although we are unsure to what extent this affect-
ed the cost to report a case of cancer. As registries entered
the second 5-year NPCR project period that began in 2000,
nine state programs transitioned from receiving planning
funding to receiving enhancement funding and began
receiving financial or in-kind support from their state
health departments as a condition of federal funding. Two
states (South Dakota and Tennessee) and the three terri-
tories are still classified as planning programs in the cur-
rent project period.
If state registry operations could be conducted more effi-
ciently, more funds would be available for their state’s can-
cer prevention and control activities. The existence of
economies of scale in federally funded, state-managed sur-
veillance programs suggests that states with fewer cases
might benefit from integrating program services with
neighboring states (e.g., by sharing resources and other
fixed-cost expenses), depending on their geographic area
and population size. In addition to reducing costs, sharing
database management resources may promote uniform
data collection and quality control practices while making
it easier for states to share information about residents
who receive diagnostic and treatment services outside
their state of residence.
Analysis limitations
This analysis has several limitations. Although we iden-
tified several important factors that seem to influence the
average annual NPCR cost to report an incident case of
cancer, we have underestimated the total cost for report-
ing a case of cancer. Comprehensive information on state
support for the operation of cancer registries was not fac-
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port, some states provide their registries with an indeter-
minate amount of direct or in-kind support from private
and public health care facilities in the form of facility
resources and staff time for surveillance-related activities.
In addition, our NPCR costs do not include the total feder-
al costs. Metropolitan-area and special-population cancer
registries participating in the SEER Program received fed-
eral support through the NCI, and these funds were not
included in our analyses. However, because the majority of
NPCR-funded state programs presumably received the
majority of their financial support from the CDC, the
direction, if not the magnitude, of the relationships we
observed are most likely correct.
Although the average NPCR cost to report a case of can-
cer seems to be higher in regions of the United States with
higher costs of living, we may have underestimated the
true impact of the CPI on registry operations. Given that
the regions are large and geographically diverse, intrare-
gional living costs may be as large as or larger than the
interregional variability.
Because of the relatively small number of state pro-
grams (44 programs), this study may have lacked the sta-
tistical power to definitively identify all factors influencing
costs. Although having a SEER Program registry within
an NPCR-funded state and having high-quality incidence
data were not significantly associated with the average
NPCR cost to report a case of cancer through the state pro-
gram, the direction of the coefficients suggests that these
factors might help explain variations in cost per case
reported. The coefficient for having a SEER Program reg-
istry within NPCR-funded cancer registries catchment
areas was negative, suggesting a lower average NPCR cost
when some of the cases are collected and reported through
the SEER Program registry. Similarly, the coefficient for
having data that met the criteria for inclusion in the
United States Cancer Statistics report was positive, sug-
gesting that additional costs are incurred when collecting
and reporting high-quality incidence data.
A scatter plot comparison of the predicted and
observed costs to report a case of cancer by each state
program reveals that large variations exist among
NPCR-funded state programs (Figure 2), and numerous
registries are spending more or less than predicted to
report a case of cancer. States that are spending more
are not necessarily less efficient than those spending
equal to or less than predicted. These states could be
using NPCR funds for data-related cancer control and
prevention activities as well as for core surveillance
activities, all of which are encouraged by NPCR.
Likewise, states with lower than predicted costs are not
necessarily more efficient. Their registries could be
receiving a larger proportion of their operating costs
from their states. These observations merely suggest
that additional analyses are needed to identify other fac-
tors to explain these discrepancies. In addition, in-depth
analyses of individual state registries, which are cur-
rently underway at the CDC, are needed to estimate the
total cost — including direct or in-kind support — to
report a case of cancer.
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Tables
Table 1. Average Annual Funds Spent, Cancer Cases Reported, and Cost per Case Reported During the First 5-Year Project
Period of the National Program of Cancer Registries (NPCR)
Average annual NPCR funds spent $382,698/$312,698 $251,420 $120,464 (Delaware)-$1,080,370 (Texas)
Average annual number of cancer cases reported 27,353/18,999 28,843 1929 (Alaska)-132,525 (California)
Average annual NPCR cost per case reported $29.20/$18.43 $38.71 $3.45 (Michigan)- $234.52 (Alaska)
Table 2. Registry and State Characteristics of Programs Participating in the National Program of Cancer Registries (NPCR)




Enhancement (existing registry) 35 79.5
Planning (newly established registry) 9 20.5
High-quality 1999 incidence data?
Yes 33 75.0
No 11 25.0
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Surveillance Epidemiology and End Results Program metropolitan area or special population within NPCR catchment area?
Yes 6 13.6
No 38 86.4
2000 consumer price index
South (167.2)a 16 36.4
West (174.8)a 10 22.7
Midwest (168.3)a 10 22.7
Northeast (179.4)a 8 18.2
Percentage of urban population (1990 census) 68.4 (15.4) 32.2 (Vermont)-100.0 (District of Columbia)
Area (sq miles) 7194 (9073) 61.4 (District of Columbia)-570,374 (Alaska)
aTreated as a continuous variable in the analysis.
Table 3. Linear Regression Model of Log Average Cost per Case Reported for Selected Registry and State Characteristics of
Programs Participating in the First 5-Year Project Period of the National Program of Cancer Registries (NPCR)
Log average annual cancer cases reported –.571 (–0.715 to –0.427; <.001) –.565 (–0.691 to –0.438; <.001)
Area (per 1000 sq miles) .002 (0.000 to 0.004; .03) .002 (0.001 to 0.004; .01)
NPCR program type (enhancement vs planning) –.374 (–0.773 to 0.024; .07) –.315 (–0.654 to 0.024; .08)
2000 consumer price index .023 (–0.005 to 0.052; .12) .025 (–0.002 to 0.051; .08)
High-quality 1999 incidence data .079 (–0.262 to 0.421; .65) NA
Percentage of urban population (1990 census) <.002 (–0.008 to 0.013; .66) NA
Surveillance Epidemiology and End Results Program metropolitan  –.063 (–0.505 to 0.378; .78) NA
area or special population within NPCR catchment area
NPCR program administered by designee .010 (–0.337 to 0.356; .96) NA
aAdjusted R2: full model, 0.73; parsimonious model, 0.71. NA indicates not applicable.
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Characteristics Mean (SD) Percentage Range
Continuous
Coefficients (95% CI; P value)a
Explanatory Variables Full Model Parsimonious Model